PATENT CLAIM ANALYSIS

Application Number: 15904265
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "220000"]

Abstract:
Provided herein are isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers, antibody-drug conjugates comprising them and methods of use for killing cells and treating disease.

Claim (Index 6):
The compound according to  claim 1 , wherein L is a linker having the structure:\n \u2014Y L \u2014X AA -PEG-, wherein:\n Y L  is a spacer molecule that links an amino acid unit of X AA  to the IQB unit; \n X AA  is an amino acid sequence having from 1 to 12 amino acids; and \n PEG is a polyethyleneglycol moiety having the structure: \n \u2014(CH 2 CH 2 O) x \u2014, wherein x is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 88.0
- Lexical Diversity: 1.16129
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15335164', '15048865', '14305643', '15182444', '15182429']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8310927396723775
- 35 USC 102 Novelty (BERT): 0.5605528599947385
- Combined Prediction Score: 0.8040387517046136
- Mean Citation Score: 413.66847400000006
- Max Citation Score: 470.99097
- Similarity Product: 316.3473417866707

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test